Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, arrives at federal court in the Brooklyn borough of New York, U.S., on Thursday, Aug. 3, 2017. The 34-year-old Shkreli, known as “Pharma Bro,” is accused of taking money from investors in his previous hedge funds and using it to start Retrophin, then using the drug-development company’s cash to pay them back. Photographer: Peter Foley/Bloomberg